Exploring the links between cognitive decline and sleep patterns in aging and Alzheimer's disease
Slow Waves During Sleep and Wakefulness: a Common Denominator for Cognitive and Attentional Disorders in Normal and Pathological Aging (Exploratory Study)
NA · Assistance Publique - Hôpitaux de Paris · NCT06501495
This study tests if changes in sleep patterns can help us understand memory problems in older adults and those with Alzheimer's disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Paris) |
| Trial ID | NCT06501495 on ClinicalTrials.gov |
What this trial studies
This study investigates how cognitive deficits associated with aging and Alzheimer's disease relate to slow wave activity measured through EEG during both sleep and wakefulness. The researchers aim to identify slow waves as a potential biomarker for sleep disturbances and daytime vigilance issues that affect memory processes. By examining these relationships, the study seeks to understand how alterations in sleep and attention impact memory encoding, consolidation, and retrieval in older adults. Participants will undergo video polysomnography and attention tasks to gather data on their cognitive and sleep patterns.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 60 to 85 with a prodromal stage of Alzheimer's disease or cognitively healthy seniors matched by age and sex.
Not a fit: Patients outside the age range of 18 to 85 or those not fluent in French may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and interventions for memory-related issues in aging and Alzheimer's patients.
How similar studies have performed: While the approach of linking EEG slow waves to cognitive decline is innovative, previous studies have explored related concepts, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
* Common Inclusion Criteria for All Three Groups: Male or female Signed informed consent Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level) Specific Inclusion Criteria for Each Group: Patients: Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ \< 600 pg/mL and ptau \> 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers Cognitively Healthy Seniors: Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test Young Adults: Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test
Where this trial is running
Paris
- Maladies du Sommeil — Paris, France (RECRUITING)
Study contacts
- Principal investigator: Marc Teichmann, MD — assisitance publique Hôpitaux de paris
- Study coordinator: Marc Teichmann, MD
- Email: marc.teichmann@aphp.fr
- Phone: 01 42 16 75 34
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Aging, Alzheimer Disease, aging, Alzheimer's disease, sleep, memory, attention, slow